RE:Big pharmas are watching us closely! Ask yourself if the acquisitions were able to destroy late-stage solid tumors? The answer is no.
Then, add this ability to do it with only a 2-doses treatment, with no side effects, all this with a standalone treatment that doesn't need adjuvants.
Then, fix your valuation, to better assess the magnitude of the task.
Bristol Myers Squibb’s $4 billion acquisition of Turning Point Therapeutics was the second highest of the half in terms of deal value, followed by GSK’s $3.3 billion play for Affinivax.